Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG is a biotechnology company focused on gene editing and the development of gene-based medicines for serious human diseases. Its core technology is the CRISPR/Cas9 platform, which is designed to make precise changes to genomic DNA. The company is advancing a pipeline across several therapeutic areas, including hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and type 1 diabetes. Its lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy developed for patients with transfusion-dependent beta-thalassemia, severe sickle cell disease, and related hemoglobin disorders. The pipeline also includes CAR T programs such as CTX112 and CTX131, in vivo candidates CTX310 and CTX320, and CTX211 for type 1 diabetes. CRISPR Therapeutics has strategic partnerships with Vertex Pharmaceuticals and is headquartered in Zug, Switzerland.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CRSP
|
$43.50
|
-26.3% Downside
|
Overvalued
|
$87.56
|
48.3% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 4, 2026
|
3.2x
|
421.2x
|
5.708 B
|
4.059 B
|
12.2%
|
99.6%
|
6.8
|
82.3%
|
